QuadLean Complex

QuadLean

Product Overview

This product contains 10 mg GLP-3RT and 10 mg Tesamorelin in lyophilized powder form for laboratory research use only.

• GLP-3RT is a triple agonist at GLP‑1, GIP, and glucagon receptors, under investigation for metabolic and weight‑related research.

• Tesamorelin is a synthetic growth hormone–releasing factor (GHRF) analog used in clinical settings to stimulate endogenous growth hormone secretion.

Key Specifications
• GLP-3RT content: 10 mg lyophilized peptide
• Tesamorelin content: 10 mg lyophilized peptide
• GLP-3RT CAS number: 2381089‑83‑2
• Tesamorelin CAS number: 218949‑48‑5

• Form: Lyophilized powder in sterile sealed vial, suitable for reconstitution with appropriate diluent under aseptic conditions

Research Benefits

GLP-3RT:
• Investigational triple agonist targeting GLP‑1, GIP, and glucagon receptors, supporting research into energy balance, body‑weight regulation, and glycemic control.

Tesamorelin:
• GHRF analog that stimulates pituitary growth hormone release, useful in models studying IGF‑1 signaling, lipolysis, and body composition.

When combined in a single research vial, this pairing may allow exploration of complementary mechanisms involving incretin and glucagon pathways (Retatrutide) alongside growth hormone axis modulation (Tesamorelin) in advanced metabolic and body‑composition research models.

Research‑Use and Medical Disclaimer
• This product is intended strictly for in vitro and in vivo laboratory research in appropriate models and is not approved for human or veterinary use, diagnostic procedures, or therapeutic applications.
• No statements regarding this product have been evaluated by the FDA or any other regulatory authority; it is not intended to diagnose, treat, cure, or prevent any disease.
• Handling should be restricted to qualified professionals familiar with peptide research, appropriate personal protective equipment, and relevant institutional and regulatory guidelines.
• Any mention of potential biological effects or mechanisms is provided solely to inform scientific research and must not be interpreted as medical advice or a recommendation for clinical use.